Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Muscles for Facial Expressions01:14

Muscles for Facial Expressions

The craniofacial muscles are a collection of approximately 20 thin skeletal muscles situated beneath the skin of the face and scalp. These muscles, primarily responsible for the vast array of human facial expressions, originate from the bones or fibrous structures of the skull and extend outwards to connect with the skin. While most skeletal muscles in the body are enveloped in thick fascia, facial muscles generally have a more delicate fascial covering, with the buccinator muscle being a...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Facial Feedback Hypothesis01:24

Facial Feedback Hypothesis

Charles Darwin proposed that facial expressions are an evolutionary adaptation for communication. He argued that these expressions are not influenced by culture but are universal across species. For example, a snarling expression with exposed teeth signals a threat in many animals, including humans. Darwin also suggested that displaying an emotion can intensify the feeling. Smiling, for example, could enhance one's sense of happiness. This idea laid the foundation for understanding the role of...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for Facial Cutaneous Squamous Cell Carcinoma in situ.

Journal of drugs in dermatology : JDD·2026
Same author

Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10%, with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma In Situ.

The Journal of clinical and aesthetic dermatology·2026
Same author

Concomitant Use of Dermo-Cosmetic Skin Care in Aesthetic Procedures: Systematic Review with Expert Panel Recommendations.

Clinical, cosmetic and investigational dermatology·2026
Same author

Nonmelanoma Skin Cancer in South Florida: A Change in the Relative Incidence of Basal and Squamous Cell Carcinoma.

The Journal of clinical and aesthetic dermatology·2025
Same author

Hell's Itch: A Case Series of a Debilitating Post-Sunburn Pruritic Syndrome in a Healthy Young Adult.

Reports (MDPI)·2025
Same author

RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity.

Toxins·2025
Same journal

The Impact of Child Life Intervention on Psychological Status and Quality of Life in Children With Cleft Lip and Palate.

The Journal of craniofacial surgery·2026
Same journal

Further Considerations for Objective Facial Paralysis Assessment.

The Journal of craniofacial surgery·2026
Same journal

Microsurgical Anatomy and Surgical Relevance of the Internal Frontal Arteries: A Cadaveric Anatomic Study.

The Journal of craniofacial surgery·2026
Same journal

Pharyngeal Airway Changes Following Bimaxillary Orthognathic Surgery in Asian Patients.

The Journal of craniofacial surgery·2026
Same journal

Endoscopic Transcaruncular Approach for Early Anterior Ethmoidal Artery Cauterization in Large Olfactory Groove Meningioma Surgery: Intraoperative Video.

The Journal of craniofacial surgery·2026
Same journal

Clinical Manifestation of Congenital Unilateral Lower Lip Palsy: A Study of 111 Patients.

The Journal of craniofacial surgery·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration
05:04

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration

Published on: May 5, 2020

Neuromodulators for Facial Aesthetics: Key Clinical Postulates.

Aysham Chaudry1, Alexandra DeVries1,2, Wilhelmina Lam1

  • 1Center for Clinical and Cosmetic Research, Aventura.

The Journal of Craniofacial Surgery
|June 16, 2026
PubMed
Summary
This summary is machine-generated.

Botulinum toxin type A (BoNT-A) offers versatile facial aesthetic treatments, but outcomes vary due to molecular potency and patient factors. This review presents postulates to optimize BoNT-A selection and injection techniques for improved results.

Keywords:
BoNT-ABoNT-Bbotoxbotulinum toxinhybrid toxinmicrobotoxneuromodulators

More Related Videos

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
19:53

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer

Published on: March 1, 2015

Related Experiment Videos

Last Updated: Jun 17, 2026

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration
05:04

Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration

Published on: May 5, 2020

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
19:53

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer

Published on: March 1, 2015

Area of Science:

  • Aesthetic Medicine
  • Neuromodulation
  • Dermatology

Background:

  • Botulinum toxin type A (BoNT-A) is a key nonsurgical treatment for facial aesthetics.
  • Its use has expanded beyond the upper face to the midface, lower face, and neck.
  • Understanding BoNT-A formulations and techniques is crucial for optimizing outcomes and minimizing complications.

Purpose of the Study:

  • To synthesize current evidence on BoNT-A mechanisms, biochemistry, and clinical applications.
  • To propose a framework of postulates to guide clinicians in optimizing BoNT-A treatments.
  • To contextualize emerging innovations within a mechanistic model for enhanced precision and efficacy.

Main Methods:

  • Review of mechanistic, biochemical, and clinical evidence.
  • Development of a theoretical framework based on toxin-receptor binding, SV2 availability, and intracellular delivery.
  • Analysis of factors influencing efficacy, onset, and duration of effect.

Main Results:

  • Clinical outcomes are influenced by molecular potency, patient biology (muscle mass, receptor density, immunogenicity), and injection variables (reconstitution, site number).
  • Molecular potency is a primary driver of clinical response, irrespective of labeled unit dose.
  • Emerging techniques like microdroplet microbotox and ultrasound guidance enhance treatment precision.

Conclusions:

  • BoNT-A products share a mechanism, but variability leads to diverse clinical outcomes.
  • A proposed model of postulates aids clinicians in optimizing toxin selection and injection strategies.
  • Innovations aim to improve the precision, efficacy, and consistency of neuromodulator treatments.